84 related articles for article (PubMed ID: 10770628)
1. Local versus systemic interleukin-2: tumor formation by wild-type and B7-1-positive murine melanoma cells.
Barnard AL; Farzaneh F; Gäken J; Darling D
Cancer Gene Ther; 2000 Feb; 7(2):207-14. PubMed ID: 10770628
[TBL] [Abstract][Full Text] [Related]
2. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
[TBL] [Abstract][Full Text] [Related]
3. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
4. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model.
Emtage PC; Wan Y; Bramson JL; Graham FL; Gauldie J
J Immunol; 1998 Mar; 160(5):2531-8. PubMed ID: 9498799
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts.
Wang J; Nakamoto T; Kasaoka Y; Usui T; Hamada H
Hiroshima J Med Sci; 2000 Mar; 49(1):73-82. PubMed ID: 10824460
[TBL] [Abstract][Full Text] [Related]
7. Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment.
Yang Y; Yang S; Ye Z; Jaffar J; Zhou Y; Cutter E; Lieber A; Hellström I; Hellström KE
Cancer Res; 2007 Mar; 67(5):2339-44. PubMed ID: 17332366
[TBL] [Abstract][Full Text] [Related]
8. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
9. Co-modification of IL-2-TNF alpha fusion gene and B7.1 gene to murine breast tumor cells leads to improved tumor rejection and vaccine effect.
Liu X; Zhang L; Zhang M; Ma Y; Xu X; Cai Y
Chin Med J (Engl); 2000 Feb; 113(2):167-71. PubMed ID: 11775545
[TBL] [Abstract][Full Text] [Related]
10. Enforced expression of MCAM/MUC18 increases in vitro motility and invasiveness and in vivo metastasis of two mouse melanoma K1735 sublines in a syngeneic mouse model.
Wu GJ; Fu P; Wang SW; Wu MW
Mol Cancer Res; 2008 Nov; 6(11):1666-77. PubMed ID: 19010815
[TBL] [Abstract][Full Text] [Related]
11. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
Tada Y; O-Wang J; Wada A; Takiguchi Y; Tatsumi K; Kuriyama T; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Feb; 10(2):134-40. PubMed ID: 12536202
[TBL] [Abstract][Full Text] [Related]
12. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12.
Coughlin CM; Wysocka M; Trinchieri G; Lee WM
Cancer Res; 1997 Jun; 57(12):2460-7. PubMed ID: 9192826
[TBL] [Abstract][Full Text] [Related]
13. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors.
Kawamura K; Bahar R; Natsume W; Sakiyama S; Tagawa M
Cancer Gene Ther; 2002 Jan; 9(1):109-15. PubMed ID: 11916240
[TBL] [Abstract][Full Text] [Related]
14. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.
Larchian WA; Horiguchi Y; Nair SK; Fair WR; Heston WD; Gilboa E
Clin Cancer Res; 2000 Jul; 6(7):2913-20. PubMed ID: 10914741
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for murine K1735 melanoma: combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulators.
Peter I; Nawrath M; Kamarashev J; Odermatt B; Mezzacasa A; Hemmi S
Cancer Gene Ther; 2002 Jul; 9(7):597-605. PubMed ID: 12082460
[TBL] [Abstract][Full Text] [Related]
18. Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity.
Moran JP; Gerber SA; Martin CA; Frelinger JG; Lord EM
Int J Cancer; 2003 Sep; 106(5):690-8. PubMed ID: 12866028
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of tumor growth by interleukin 10 gene transfer in B16(F10) melanoma cells.
Walos S; Szary J; Szala S
Acta Biochim Pol; 1999; 46(4):967-70. PubMed ID: 10824866
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
